Danaher Corporation completes acquisition of Aldevron for $9.6 billion
Danaher completed the acquisition of Aldevron for $9.6 billion in the fall of 2021. Aldevron is a high-quality plasmid DNA, mRNA and proteins manufacturer that mainly services biotechnology and pharmaceutical customers across research, clinical and commercial fields. Aldevron joined Danaher’s life sciences segment and has expanded the company’s capabilities into the field of genomic medicine. Aldevron will benefit from Danaher’s global reach, increase its ability to support a growing number of customers and bring vaccines and therapies to the market faster.
M&AIn response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.
Lorem Ipsum text header Report Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.
Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.